JERSEY CITY, N.J. (PRWEB) February 17, 2020
Craig Lipset, Scott Ballenger Provide Clinical Trial Sponsor, Recruiter Perspectives
TrialScope announces the appointment of Craig Lipset and Scott Ballenger to the TrialScope Connect advisory board. TrialScope Connect is an online clinical trial recruitment collective designed to address the challenges stakeholders face in accurately matching patients to trials. In advance of the platform’s launch, TrialScope is accepting partner applications from sponsors, healthcare data companies and patient advocacy groups.
Lipset, former head of Clinical Innovation and venture partner at Pfizer, is a recognized leader in clinical research and medicine development. He is an advisor to technology and biopharmaceutical companies, leading universities and the venture community. He serves on numerous boards, including the MedStar Health Research Institute, the People-Centered Research Foundation (the central office for PCORnet) and the Editorial Board for Therapeutic Innovation & Regulatory Science.
Lipset has received the red jacket “hall of fame” recognition among the PharmaVOICE most inspiring people in the life sciences. He has been recognized among Pharmaceutical Executive’s Emerging Leaders, CenterWatch Top 20 Innovators in Clinical Trials, the Medicine Maker Power List and the AlleyWatch Who's Who in eHealth.
"Study recruitment has struggled for years because of the challenge connecting those with access to patients to research sponsors and CROs,” Lipset said. ”TrialScope Connect fills this need with a transparent and frictionless approach that helps all suppliers and sponsors. It reduces burden for trial sites and, most importantly, enables increased awareness for patients who will benefit from research participation."
Ballenger is president of the Trial Acceleration Institute, a consultancy serving start-ups to Fortune 50 in the creation and monetization of new solutions for the healthcare market. He has been a founding team member of several start-up companies; contributed to three venture capital rounds, two IPOs, one turnaround, and multiple acquisitions; and has propelled two companies from early-stage to industry leader in fewer than three years. He has advised more than 60 pharmaceutical and biotech companies In addition, Ballenger himself has been a volunteer in several clinical trials.
“It is well documented that clinical trials are increasing in complexity," said Ballenger, “and this creates a more challenging patient profile for recruiting. The TrialScope Connect data-driven API collective will unlock broader and deeper patient access opportunities to address the growing patient profile challenge.”
“We look forward to the expertise and insight that Craig and Scott will bring our advisory board,” said Mike Wenger, TrialScope Vice President of Patient Engagement, who is spearheading the initiative. Wenger is founder of Clinical Trial Connect, which was recently acquired by TrialScope and whose technology created the foundation for the TrialScope Connect collective.
“The involvement and buy-in of Craig and Scott, stakeholders that sat on opposite sides of the table, highlights the opportunity TrialScope Connect will have in addressing inefficiencies in clinical trial recruitment,” Wenger said. “It also is a reflection of the collaborative environment we hope to create, bringing together study sponsors and healthcare data companies, along with advocacy and disease organizations, to better match patients to clinical trials.”
For more information on TrialScope Connect partnership opportunities, contact TrialScope at firstname.lastname@example.org.
TrialScope technology powers the authoritative clinical trial data hub that enables sponsors to streamline trial disclosure, expand access to data, and connect the dots between patients and clinical trials. Sixteen of the top 20 industry clinical trial sponsors rely on TrialScope’s suite of data transparency, disclosure, patient engagement and recruiting solutions to build public trust and accelerate clinical development timelines. To learn more about TrialScope, visit TrialScope.com.